tetano
Editor, Senior Moderator
Curr Probl Cardiol
. 2022 Mar 25;101187.
doi: 10.1016/j.cpcardiol.2022.101187. Online ahead of print.
Chronic thromboembolic pulmonary hypertension (CTEPH): a review of another sequel of severe post-Covid-19 pneumonia
Guillermo Cueto-Robledo[SUP] 1 [/SUP], Ernesto Roldan-Valadez[SUP] 2 [/SUP], Luis-Eugenio Graniel-Palafox[SUP] 3 [/SUP], Marisol Garcia-Cesar[SUP] 4 [/SUP], Maria-Berenice Torres-Rojas[SUP] 5 [/SUP], Rocio Enriquez-Garcia[SUP] 6 [/SUP], Hector-Daniel Cueto-Romero[SUP] 7 [/SUP], Nathaly Rivera-Sotelo[SUP] 8 [/SUP], Angel-Augusto Perez-Calatayud[SUP] 9 [/SUP]
Affiliations
Abstract
The spectrum of pulmonary parenchymal and vascular pathologies related to the COVID-19 have emerged. There is evidence of a specific susceptibility related to thrombotic microangiopathy in situ and a complex immune-inflammatory cascade, especially in the pulmonary vascular bed. The potential to lead to transient or self-correcting sequelae of pulmonary vascular injury will only become apparent with longer-term follow-up. In this review, we aimed to present the findings in a group of patients with severe pneumonia due to covid-19 complicated by acute pe documented by chest angiography, who during a follow-up of more than three months with oral anticoagulant met clinical, hemodynamic, and imaging criteria of chronic thromboembolic pulmonary hypertension. We present a brief review of the epidemiology, pathophysiology, clinical findings, comorbidities, treatment, and imaging findings of chronic thromboembolic pulmonary hypertension as a sequel of severe post-covid-19 pneumonia; and compared and discussed these findings with similar reports from the medical literature.
Keywords: chronic thromboembolic pulmonary hypertension (CTEPH); interstitial lung disease; pulmonary embolism; pulmonary hypertension; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2022 Mar 25;101187.
doi: 10.1016/j.cpcardiol.2022.101187. Online ahead of print.
Chronic thromboembolic pulmonary hypertension (CTEPH): a review of another sequel of severe post-Covid-19 pneumonia
Guillermo Cueto-Robledo[SUP] 1 [/SUP], Ernesto Roldan-Valadez[SUP] 2 [/SUP], Luis-Eugenio Graniel-Palafox[SUP] 3 [/SUP], Marisol Garcia-Cesar[SUP] 4 [/SUP], Maria-Berenice Torres-Rojas[SUP] 5 [/SUP], Rocio Enriquez-Garcia[SUP] 6 [/SUP], Hector-Daniel Cueto-Romero[SUP] 7 [/SUP], Nathaly Rivera-Sotelo[SUP] 8 [/SUP], Angel-Augusto Perez-Calatayud[SUP] 9 [/SUP]
Affiliations
- PMID: 35346727
- DOI: 10.1016/j.cpcardiol.2022.101187
Abstract
The spectrum of pulmonary parenchymal and vascular pathologies related to the COVID-19 have emerged. There is evidence of a specific susceptibility related to thrombotic microangiopathy in situ and a complex immune-inflammatory cascade, especially in the pulmonary vascular bed. The potential to lead to transient or self-correcting sequelae of pulmonary vascular injury will only become apparent with longer-term follow-up. In this review, we aimed to present the findings in a group of patients with severe pneumonia due to covid-19 complicated by acute pe documented by chest angiography, who during a follow-up of more than three months with oral anticoagulant met clinical, hemodynamic, and imaging criteria of chronic thromboembolic pulmonary hypertension. We present a brief review of the epidemiology, pathophysiology, clinical findings, comorbidities, treatment, and imaging findings of chronic thromboembolic pulmonary hypertension as a sequel of severe post-covid-19 pneumonia; and compared and discussed these findings with similar reports from the medical literature.
Keywords: chronic thromboembolic pulmonary hypertension (CTEPH); interstitial lung disease; pulmonary embolism; pulmonary hypertension; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).